Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer

• DOI: 10.3389/fphar.2024.1391896
• Publication Date: 2024-06-20T05:10:18Z
• Authors: Gengwei Huo; Ying Song; Wei Liu; Hua Guo; Peng Chen
• Keywords: Carboplatin

Objective In the double-blind, phase III, placebo-controlled RUBY randomized clinical trial, dostarlimab plus carboplatin-paclitaxel significantly increased survival among patients with primary advanced or recurrent endometrial cancer (EC). We conducted a cost-effectiveness analysis of in combination chemotherapy these stratified by mismatch repair-deficient (dMMR) and repair-proficient (pMMR) subgroups from perspective United States payer. Materials methods A Markov model three states was employed to simulate who were administered either based on trial. Quality-adjusted life-years (QALYs), lifetime costs, incremental ratio (ICER) calculated willingness-to-pay (WTP) threshold $150,000 per QALY. Both univariate probabilistic sensitivity analyses carried out explore robustness model. Results dMMR EC, achieved an additional 5.48 QALYs at cost $330,747 compared alone, resulting ICER $60,349.30 pMMR there 1.51 gained extra $265,148, yielding $175,788.47 With 15.2% discount dostarlimab, decreased QALY EC. The revealed that utility progression-free (PFS), progressive disease (PD) had most significant impacts outcomes. Probabilistic 100% likelihood being considered cost-effective for WTP whereas this only 0.5% Conclusion Dostarlimab EC payer QALY, but not Lowering prices could potentially enhance treatment